Hummingbird, Tempus collaborate to harness AI-driven precision medicine

One percent of all solid tumors harbor NRG1 fusions, a rare genetic mutation that drives malignancies.

Singapore biotech company Hummingbird Bioscience has announced a collaboration with technology company Tempus to harness AI and big data in support of a biomarker-driven clinical trial for Hummingbird’s anti-HER3 antibody, HMBD-001, including those that harbor neuregulin 1 (NRG1) fusions.

NRG1 fusions are a rare genetic mutation that are increasingly recognized as a driver of multiple tumor malignancies, and an actionable target for HER3 targeted therapy. One percent of all solid tumors harbor NRG1 fusions, which deems the necessity to identify this patient population and develop therapies that can treat them.

As part of the collaboration, Hummingbird will leverage Tempus’ AI-enabled platform and proprietary data, as well as joining its TIME Trial Network, for rapid identification, site activation, and efficient enrollment of cancer patients who have NRG1 fusions and meet eligibility criteria for HMBD-001 clinical trials.

“We are excited to collaborate with Tempus to leverage their just-in-time clinical trial program and apply Hummingbird’s deep knowledge of disease driving protein mechanisms in order to identify patients with actionable genetic abnormalities,” Hummingbird co-founder and chief executive officer Dr Piers Ingram said.

“This collaboration is an opportunity to identify those patients who could benefit from this investigational therapy, and if they are eligible, rapidly open the trial just for them,” Tempus vice president of operations, therapies Amy Franzen said.

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia